Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir versus standard of care for adenovirus infection in high-risk pediatric allogeneic HCT recipients
2017-001735-39Phase 2Completed
- Sponsor
- Chimerix Inc.
- Start
- Nov 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in adenoviral infection comparing Brincidofovir with Standard of care (2 arms). Primary endpoints: Time-averaged area under the concentration-time curve for adenovirus viremia through Week 16 and Safety and overall tolerability. Started Nov 2017; status: completed.
02
Drugs
brincidofovir
03
Conditions
adenoviral infection
Beyond the preview
Go deeper on 2017-001735-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001735-39.